Factory 99% Mycophenolate Mofetil Powder CAS 115007-34-6 Mycophenolate Mofetil

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A624
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Mycophenolate Mofetil
• CAS: 115007-34-6
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Immunosuppression
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Mycophenolate Mofetil
Appearance	White Powder
CAS NO.	115007-34-6
MF	C23H31NO7
Storage	Keep in a cool, dry, dark location

 

Mycophenolate Mofetil is a prodrug that is metabolized in vivo to its active form, mycophenolic acid (MPA). MPA inhibits IMPDH, an enzyme essential for the synthesis of guanine nucleotides, thereby blocking the proliferation of T and B lymphocytes, which are key mediators of immune responses.

 

1. Organ Transplantation: Mycophenolate Mofetil is a cornerstone of immunosuppressive therapy following organ transplantation, including kidney, heart, liver, and lung transplants. It helps to reduce the risk of allograft rejection.
2. Autoimmune Diseases: It is also used to treat autoimmune disorders such as lupus nephritis, a kidney inflammation caused by systemic lupus erythematosus, and certain types of vasculitis.
3. Prevention of Graft-Versus-Host Disease: In some cases, Mycophenolate Mofetil may be used to prevent graft-versus-host disease (GVHD) in patients undergoing allogeneic hematopoietic stem cell transplantation.

1. Immunosuppression: By inhibiting IMPDH and reducing lymphocyte proliferation, Mycophenolate Mofetil suppresses the immune system, thereby preventing allograft rejection and autoimmune attacks on host tissues.
2. Anti-Inflammatory Effects: MPA may also exhibit direct anti-inflammatory properties, reducing inflammation and tissue damage in autoimmune diseases.
3. Improved Patient Outcomes: The use of Mycophenolate Mofetil in immunosuppressive protocols has been associated with improved patient survival and allograft function in transplant recipients, as well as reduced disease activity in patients with autoimmune disorders.